Semnur Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | — | $2.5M | $1.7M | — | — |
| SG&A Expense | — | $157.9M | $3.0M | — | — |
| Operating Income | — | $-160.4M | $-4.7M | $-3.2M | — |
| Operating Margin | — | — | — | — | — |
| Interest Expense | — | — | $96.2K | $36.9K | — |
| Pretax Income | — | $0 | $0 | — | — |
| Income Tax Expense | — | $0 | $0 | — | — |
| Net Income | — | $-160.4M | $-4.7M | $632.5K | $-419.4K |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | — | $-0.78 | $-0.02 | — | — |
| EPS (Diluted) | — | $-0.78 | $-0.02 | — | — |
| Shares Outstanding (Basic) | 230.2M | 204.8M | 200.0M | — | — |
| Shares Outstanding (Diluted) | 230.2M | 204.8M | 200.0M | — | — |
| Dividends Per Share | — | — | — | — | — |